All mice and ferrets receiving Cambridge’s AI-designed bird-flu vaccine survived multi-variant animal tests; approximately half receiving existing vaccines survived.

The candidate vaccine was jointly developed by the University of Cambridge and a university spinout. Researchers collected bird-flu genetic-sequence data from global surveillance programs and used AI tools to analyze the data. They designed a series of “superantigens” containing shared antigenic features of these viruses, then used cell testing to select antigens for the vaccine.

The animal experiments tested protection against genetically different bird-flu variants. All mice and ferrets receiving the candidate survived the challenges, compared with approximately half of the animals receiving existing bird-flu vaccines. The tested variants had previously caused human infections, but the supplied report does not disclose animal counts, variant-by-variant results, or statistical confidence measures.

The stated research objective is broader protection against viral evolution. Research leader Professor Jonathan Heeney said AI tools can substantially accelerate vaccine design. Cambridge’s announcement contrasted the approach with existing bird-flu vaccines, which principally target particular identified strains and require updating as viruses change.

The findings remain animal-study results rather than demonstrated human protection. The team plans human clinical trials, and the report says the research has been published in Cell Reports Medicine. No completed human trial, regulatory authorization, or commercial deployment is reported in the supplied source.